Relenza

Relenza is a brand name of zanamivir, approved by the FDA in the following formulation(s):

RELENZA (zanamivir - powder; inhalation)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: July 26, 1999
  
  Strength(s): 5MG ^[RLD]

Has a generic version of Relenza been approved?

No. There is currently no therapeutically equivalent version of Relenza available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Relenza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents
  Patent 5,360,817
  Issued: November 1, 1994
  Inventor(s): von Izstein; Laurence M. & Wu; Wen-Yang & Phan; Tho V. & Danylec; Basil & Jin; Betty
  Assignee(s): Biota Scientific Management Pty Ltd
  Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid, pharmaceutical formulations thereof, methods for their preparation .and their use in the treatment of viral infections, in particular influenza, are described.
  
  Patent expiration dates:
  
  
  • July 26, 2013
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents
  Patent 5,648,379
  Issued: July 15, 1997
  Inventor(s): Von Itzstein; Laurence Mark & Wu; Wen-Yang & Van Phan; Tho & Danylec; Basil & Jin; Betty & Colman; Peter Malcolm & Varghese; Joseph Noozhumurry
  Assignee(s): Biota Scientific Management Pty., Ltd.
  Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid, pharmaceutical formulations thereof, methods for their preparation and their use in the treatment of viral infections, in particular influenza, are described.
  
  Patent expiration dates:
  
  
  • July 15, 2014
    
    ✓ 
    Patent use: ZANAMIVIR FOR INHALATION
  
  
  
  • July 15, 2014
    
    ✓ 
    Patent use: TREATMENT OF INFLUENZA
  
  
  
  • July 15, 2014
    
    ✓ 
    Patent use: PROPHYLAXIS OF INFLUENZA
  
  



• 
  Crystalline N-acetyl neuraminic acid derivatives and process for their preparation
  Patent 6,294,572
  Issued: September 25, 2001
  Inventor(s): Williamson; Christopher & White; William James & Patel; Vipulkumar
  Assignee(s): Biota Scientific Management Pty Ltd.
  Two useful crystal hydrates of 5-acetamido-2,3,4,5-tetradeoxy-4-guanidino-D-glycero-D-galacto-non-2-enopy ranosonic acid have either a low or high aspect ratio. These crystalline N-acetyl neurominic acid derivatives are favored for pharmaceutical formulation because of their physical properties. For example, the low aspect ratio crystal has good flow properties, and the high aspect ratio crystal has a stable water content over time.
  
  Patent expiration dates:
  
  
  • December 15, 2014
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Relenza Consumer Information (Drugs.com)
• Relenza Consumer Information (Wolters Kluwer)
• Relenza Consumer Information (Cerner Multum)
• Relenza Advanced Consumer Information (Micromedex)
• Relenza AHFS DI Monographs (ASHP)
• Zanamivir Consumer Information (Wolters Kluwer)
• Zanamivir Consumer Information (Cerner Multum)
• Zanamivir Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
• Zanamivir AHFS DI Monographs (ASHP)